$RNXT News

Ascendiant Capital Maintains Buy on RenovoRx, Raises Price Target to $14

RenovoRx Announces FDA Orphan Drug Designation Of Oxaliplatin For The Treatment Of Pancreatic Cancer

RenovoRx Announces Online Publication Of Abstract From Pharmacokinetic And Pharmacodynamic Sub-Study Of Ongoing Phase III TIGeR-PaC Clinical Trial In Connection With 2026 ASCO Annual Meeting

RenovoRx Reports Q1 2026 Results: Full Earnings Call Transcript

RenovoRx Affirms FY2026 Sales Guidance of $3.000M-$4.000M vs $3.244M Est.

RenovoRx Q1 Adj. EPS $(0.08), Inline, Sales $563.000K Beat $463.250K Estimate.

Ascendiant Capital Maintains Buy on RenovoRx, Raises Price Target to $13.5

HC Wainwright & Co. Reiterates Buy on RenovoRx, Maintains $3 Price Target

RenovoRx Secures Notice Of Allowance From Japan Patent Office For Application Titled "Method and Apparatus for Delivering an Agent Through the Vasa Vasorum"

RenovoRx Q4 EPS $(0.08), Inline, Sales $238.000K Miss $419.750K Estimate

RenovoRx Announces Key Phase III Enrolment Milestone For RenovoCath Use In IAG To Minimize Therapy Toxicity While Treating Advanced Pancreatic Cancer

RenovoRx Announces Key Phase III Enrolment Milestone For RenovoCath Use In IAG To Minimize Therapy Toxicity While Treating Advanced Pancreatic Cancer

RenovoRx Announces $10M At-The-Market Private Placement For Oversubscribed Common Stock And Milestone Warrant Private Placement

RenovoRx Announces 12 U.S. Centers Using Its RenovoCath Device

Ascendiant Capital Maintains Buy on RenovoRx, Raises Price Target to $13

RenovoRx Creates RenovoCath Medical Advisory Board For Its Clinical, Strategic Initiatives

RenovoRx Appoints Mark Voll CFO, Effective Feb. 1

RenovoRx To Present New Clinical Data At 2026 Society Of Interventional Oncology Annual Scientific Meeting On Feb. 6

RenovoRx's Abstract Submission Accepted

RenovoRx shares are trading higher. The company announced that it will present a new clinical data abstract from a pharmacokinetic and pharmacodynamic sub‑study of its ongoing Phase III TIGeR‑PaC clinical trial at the ASCO GI.